Federal Trade Commission v. AbbVie Inc, No. 18-2621 (3d Cir. 2020)
Annotate this CaseThis opinion or order relates to an opinion or order originally issued on September 30, 2020.
Download PDF
UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT Nos. 18-2621, 18-2748 & 18-2758 FEDERAL TRADE COMMISSION, Appellant in 18-2621 v. ABBVIE INC; ABBOT LABORATORIES; UNIMED PHARMACEUTICALS, LLC; BESINS HEALTHCARE, INC; *TEVA PHARMACEUTICALS USA INC AbbVie Inc; Abbott Laboratories; Unimed Pharmaceuticals, LLC, Appellants in No. 18-2748 Besins Healthcare, Inc., Appellant in No. 18-2758 (Dismissed Pursuant to Court’s 3/12/19 Order.) (E.D. Pa. No. 2-14-cv-05151) Present: HARDIMAN, PORTER and PHIPPS, Circuit Judges _________________________________ORDER________________________________ On further review of the opinion filed in the above captioned cases, the Court has determined that a word should be added on page 96. The opinion is hereby amended so that the last sentence of the first paragraph on p. 96 reads, “To the extent the FTC did not timely raise this argument in the District Court, it is forfeited on appeal.” The Clerk is directed to file the amended opinion simultaneously with this order. By the Court, s/ Thomas M. Hardiman Circuit Judge Dated: December 4, 2020 CJG/cc: All Counsel of Record
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
